ClinicalTrials.gg
Active, not recruitingNCT07443293Updated Jun 25, 2026

IMPACT 360 for Parkinson's Disease

A Phase 2 interventional study of Exercise and Meditation in Parkinson's Disease (PD) and REM Sleep Behavior Disorder, sponsored by University of British Columbia. Active, not recruiting at 1 site in Canada. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by University of British Columbia · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Oct 2024, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Parkinson Disease by University of British Columbia — 7 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · University of British Columbia.

Planned enrollment
2nd of 13
60 · median 40
Started
2024
with 3 others
Phase 2
3 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Parkinson Disease by University of British Columbia, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 3 in phase 2, and was the 14th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 14 studies in Parkinson Disease by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by University of British Columbia, or all of them as a file.
02

Study summary

The IMPACT 360 study will evaluate the effects of a combined intervention of exercise, mindfulness, and nutrition on 8 key indicators of health and the mechanisms that drive these changes. 60 subjects aged 40 to 85 with a current diagnosis Parkinson's disease will be recruited. This study will follow a partial crossover design. All participants will receive the intervention. Participants randomized into the intervention group after their baseline screening will receive the 6-month intervention. Those randomized into the waitlist group will complete another assessment at the end of the 6-month care as usual phase before receiving the intervention.

Read the detailed description

Despite its rapidly rising prevalence and status as the second most common neurodegenerative disease worldwide, Parkinson's disease (PD) remains without pharmacological or neuroprotective therapies to prevent or slow down disease progression. While there is marked heterogeneity in its presentation, PD is diagnostically linked to motor impairments, including bradykinesia (slowness of movement), tremors, rigidity, dyskinesia (involuntary, erratic movement), and dystonia (involuntary muscle contraction causing slow, repetitive movement), as well as cognitive decline and neuroinflammation, negatively affecting activities of daily living. Additionally, PD may have a very long prodromal phase, which can last up to decades. During this period, individuals may develop non-motor symptoms, including REM-Sleep Behaviour Disorder (RBD), a nervous system disorder. Typically, during REM sleep, individuals experience a loss of muscle tone, which is absent from those with RBD. As such, RBD is generally characterized by a tendency to act out dreams. Due to the very high specificity for people with RBD to later develop PD26, the study of individuals with idiopathic RBD is particularly valuable, as pathology to the brain is limited at this time. Information about the early, premotor stages of PD can be gathered at a time when therapeutic interventions are most promising. Current research suggests that exercise, meditation, and nutrition have beneficial neuroprotective effects. Physical activity has been associated with improved learning and memory and cognitive function. Long-term exercise has also been shown to upregulate anti-inflammatory and neuroprotective factors. Research examining the effects of mindfulness interventions have found significant increases in grey matter and functional connectivity. Diets high in fruit and vegetable content and low in higher-inflammatory foods such as red meats and sweets, like the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, have been shown to increase levels of plasma brain-derived neurotrophic factor. The benefits of these individual interventions have been shown, but emerging evidence suggests that combined interventions are more powerful than isolated ones. The crucial next step is to study the impact of a multimodal program on brain health and to comprehensively examine underlying mechanisms.

Risk factors for many neurological conditions can be modified, indicating that some instances of neurological dysfunction can be prevented through lifestyle modifications. For example, potentially modifiable risk factors for dementia include: high blood pressure, Type 2 diabetes, obesity, lack of physical activity, hearing loss, and poor diet. Many of these can be improved through exercise and nutrition and there is evidence that this combined lifestyle intervention may also be beneficial for those already diagnosed with neurological conditions. A comprehensive examination evaluating health and wellness in people with Parkinson's disease (PwP) and people with RBD (PwRBD) will help us to understand the mechanisms behind the benefits of this combined intervention and how the interactive effects impact one's overall health.

The aim of this study is to evaluate the effects of a multimodal intervention in PwP and PwRBD and to elucidate the mechanisms driving the associated changes. The comprehensive assessment ("360 degree approach") will focus on 8 key areas of health: cognition, inflammation, microbiome diversity, sleep quality, neurological imaging markers, physical fitness, cardiovascular health, and social and mental well-being. Glucose metabolism will be evaluated as an optional 9th key area of health.

03

Conditions studied

  • Parkinson's Disease (PD)
  • REM Sleep Behavior Disorder

Keywords

  • Exercise
  • Mindfulness
  • Nutrition
  • Microbiome
  • Well-Being
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age 40-85 years
  • A diagnosis of either PD, based on the Movement Disorder Society (MDS) criteria, OR, RBD, through a polysomnography
  • Hoehn \& Yahr score of 1 to 2
  • Able to fill out questionnaires
  • Able to follow instructions and directions as required by the intervention.
  • Have access to the necessary technologies (i.e., a working smartphone for Fitbit, a laptop or tablet for Zoom) as required by the intervention.

Exclusion Criteria:

  • Any chronic medical condition which would affect ability to participate in exercise
  • Any for exercise based on the Physical Activity Readiness for Everyone Questionnaire (PAR-Q+) and medical clearance form
  • Significant cognitive impairment, depression, or eating disorder
  • Score \<21/30 on the (MoCA)
  • Any contraindication to MRI scanning; such as implanted metal clips or wires (see list below)
  • Participants who were told by a medical doctor that they need to be medically supervised for exercise
  • Participants currently doing 180 minutes or more of moderate-vigorous intensity exercise per week AND either of the following:

Completion of a Mindfulness-Based Stress Reduction course OR; Score >8/15 in the MIND Diet Questionnaire

  • Significant or unstable cardiovascular or respiratory disease
  • Severe/multiple head trauma(s)
  • Subjects who are pregnant or breastfeeding
  • Subjects with a history or major episodes of drug or alcohol abuse
  • Chronic/acute bacterial/viral infection
  • GI cancer
  • Inflammatory bowel disease

Exclusion for MRI scanning:

  • Individuals weighing > 400 lbs (limit of MRI machine)
  • Artificial heart valve
  • Brain aneurysm clip
  • Electrical stimulator for nerves or bones
  • Ear or eye implant
  • Implanted drug infusion pump
  • Coil, catheter, or filter in any blood vessel
  • Orthopedic hardware (artificial joint, plate, screws)
  • Other metallic prostheses
  • Shrapnel, bullets, or other metal fragments
  • Surgery or tattoos (including tattooed eyeliner) in the last six weeks
  • Brain surgery
  • Have a cardiac pacemaker, wires or defibrillator
  • Have had an injury where a piece of metal lodged in the eye or orbit
  • Have a ferromagnetic aneurysm clip
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Exercise, Diet, Mindfulness

    The intervention group will start the intervention immediately following their baseline assessment. They will undergo another assessment after the 6 month intervention period. Interventions: Behavioural: Exercise Behavioural: Meditation Behavioural: Diet

    Behavioral: Exercise · Behavioral: Meditation · Behavioral: Diet

  • No intervention
    Waitlist Group

    Participants randomized into the waitlist group will undergo a baseline assessment, and will then be encouraged to continue their daily activities as usual for 6 months. Physical activity and sleep will be monitored during this time using wearable devices. Links to questionnaires will be emailed monthly. After the 6-month waitlist period, participants will undergo a second assessment prior to starting the intervention. The multimodal intervention will be 6-months in length, using the same measures of adherence, and will be followed by a final assessment.

Interventions

  • BehavioralExercise

    The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months.

  • BehavioralMeditation

    The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes. Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention.

  • BehavioralDiet

    The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.

06

What researchers measure

Primary outcomes

  1. Cognition - NIH Toolbox Cognitive Battery

    Cognition will be measured using the National Institutes of Health (NIH) Toolbox Cognitive battery (NIHTB-CB). Testing is done pre- and post-intervention to compare scores.

    Time frame: 6 Months

  2. Cognition- Montreal Cognitive Assessment

    Cognition will be measured using the Montreal Cognitive Assessment (MoCA). Testing is done pre- and post-intervention to compare scores.

    Time frame: 6 Months

  3. Cognition- Parkinson's Disease Cognitive Rating Scale [Time Frame: 6 Months]

    Cognition will be measured using the Parkinson's Disease Cognitive Rating Scale (PD-CRS). Testing is done pre- and post-intervention to compare scores.

    Time frame: 6 Months

  4. Inflammation and Biomarkers in Serum- High Sensitivity C-Reactive Protein

    Systemic inflammation will be assessed by measuring concentrations of high sensitivity C-reactive protein (hs-CRP). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  5. Inflammation and Biomarkers in Serum - Interleukin-1β

    Systemic inflammation will be assessed by measuring concentrations of interleukin-1β (IL-1β). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  6. Inflammation and Biomarkers in Serum - Interleukin-6

    Systemic inflammation will be assessed by measuring concentrations of interleukin-6 (IL-6). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  7. Inflammation and Biomarkers in Serum - Tumour Necrosis Factor Alpha

    Systemic inflammation will be assessed by measuring concentrations of Tumour Necrosis Factor Alpha (TNFa). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  8. Inflammation and Biomarkers in Serum - Interleukin-8

    Systemic inflammation will be assessed by measuring concentrations of interleukin-8 (IL-8). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  9. Inflammation and Biomarkers in Serum - Interleukin-10

    Systemic inflammation will be assessed by measuring concentrations of interleukin-10 (IL-10). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  10. Inflammation and Biomarkers in Serum - Interleukin-18

    Systemic inflammation will be assessed by measuring concentrations of interleukin-18 (IL-18). Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  11. Inflammation and Biomarkers in Serum - Calprotectin

    Systemic inflammation will be assessed by measuring concentrations of calprotectin. Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  12. Inflammation and Biomarkers in Serum - cortisol

    Systemic inflammation will be assessed by measuring concentrations of cortisol. Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  13. Microbiome Diversity

    Stool samples will be analyzed for gut microbiome composition by shallow shotgun metagenome sequencing. Samples will be taken pre- and post-intervention to assess changes.

    Time frame: 6 Months

  14. Sleep Efficiency

    Sleep efficiency (total sleep time/time spent in bed) will be measured through a wearable device with an accelerometer. This device will also measure other components of sleep quality such as sleep onset latency, total sleep time and wake after sleep onset.

    Time frame: 6 Months

  15. Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index will be used to collect subjective sleep quality data on a monthly basis.

    Time frame: 6 Months

  16. Total Grey Matter Volume

    Total grey matter volume will be measured using an MRI. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  17. Hippocampal Volume

    Hippocampal volume will be measured using an MRI. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  18. White matter hyperintensities volume

    White matter hyperintensities volume will be measured using an MRI. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  19. Myelin Water

    Myelin water imaging will be collected using resting state functional MRI. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  20. Functional MRI

    A flanker task will be administered during the MRI to examine selective attention, inhibitory function, and executive control. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  21. Maximal oxygen consumption (VO2 Max)

    Predicted maximal oxygen consumption will be measured using a six-minute walk test. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  22. Heart Rate Recovery

    Heart rate recovery will be measured using a three-minute step test. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  23. Berg Balance Assessment

    A Berg Balance Assessment will be used to measure participants balance. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  24. Dynamic Gait Index

    The Dynamic Gait Index will be used to measure participants gait. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  25. Timed Up and Go Test

    The Dynamic Gait Index will be used to measure participants gait. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  26. 30 Second Sit to Stand Test

    Functional lower extremity strength with be assessed using the 30 second sit to stand test. Testing is done pre- and post-intervention to compare scores.

    Time frame: 6 Months

  27. Dual-Energy X-Ray Absorptiometry (DEXA)

    Body composition, such as body fat and muscle mass, will be measured using Dual-energy X-ray Absorptiometry. Testing is done pre- and post-intervention to compare scores.

    Time frame: 6 Months

  28. Physical Activity Levels

    Physical activity levels will be measured through a wearable device to help ensure adherence and effectiveness of the exercise intervention. Data will be collected throughout the study.

    Time frame: 6 Months

  29. Heart Rate

    Heart rate will be measured through a wearable device to help ensure adherence and effectiveness of the exercise intervention. Data will be collected throughout the study.

    Time frame: 6 Months

  30. Fried Frailty Index

    Physical frailty will be assessed using the fried frailty index. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  31. Blood Pressure

    Blood pressure will be measured pre- and post-intervention to compares scores.

    Time frame: 6 Months

  32. Weight

    Weight will be measured pre- and post-intervention to compares scores.

    Time frame: 6 Months

  33. Framingham Risk Score

    Cardiovascular health will be assessed using the Framingham Risk Score. This score includes measurements of age, total cholesterol, smoking status, HDL level, diabetes status, systolic blood pressure and treatment status. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  34. NIH Toolbox- Emotional Battery

    Social, emotional, and mental well-being will be evaluated using the NIH Toolbox-Emotional Battery. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  35. World Health Organization (WHO) Quality of Life Questionnai

    Quality of life will be evaluated using the World Health Organization (WHO) Quality of Life Questionnaire. Testing is done pre- and post-intervention to compares scores.

    Time frame: 6 Months

  36. Freiburg Mindfulness Inventory

    Questionnaires related to mindfulness will be administered throughout the study at monthly intervals.

    Time frame: 6 Months

  37. Mindful Attention Awareness Scale

    Questionnaires related to mindfulness will be administered throughout the study at monthly intervals.

    Time frame: 6 Months

  38. Multidimensional Assessment of Interoceptive Awareness

    Questionnaires related to mindfulness will be administered throughout the study at monthly intervals.

    Time frame: 6 Months

  39. Motor and Non-motor Complications and Experiences of Daily Living

    Motor and non-motor complications and experiences of daily living will be measured using the MDS-UPDRS. Testing is done pre- and post-intervention to compare scores.

    Time frame: 6 Months

  40. Glucose Metabolism

    Glucose metabolic patterns will be estimated by positron emission tomography (PET) using the radiotracer \[18F\]fluorodeoxyglucose. Testing is done pre- and post-intervention to compare patterns.

    Time frame: 6 Months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 106 non-industry phase 2 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 26 months is below that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Oct 28, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443293
Responsible party
Silke Cresswell (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Mar 2, 2026
Start date
Oct 28, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Silke Appel-Cresswell, MD, FRCPC
principal investigator · University of British Colombia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion